Factor XII Explored with AlphaFold - Opportunities for Selective Drug Development
Thrombosis and Haemostasis · 01.02.2023 · 123 (02) · 177-185
DOI: 10.1055/a-1951-1777 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.02.2023. Verfasst von Rowan Frunt und 4 weiteren Autor:innen. Beteiligte Einrichtung: CDL Research, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Factor XII, Thrombosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Trombosestichting Nederland.
Abstract (Originalsprache)
Medical device associated thrombosis is an important clinical problem. This type of thrombosis can result from Factor XII (FXII) binding to non-natural surface materials and subsequent activation of the contact pathway. This drives the development of new therapeutic strategies to block this pathway and information on the structural properties of FXII should catalyse this quest. Presently, there is no publicly available crystal structure of full-length FXII. However, the AlphaFold Protein Structure Database provides a model structure. We here explore this model in combination with previous structure-function studies to identify opportunities for selective pharmacological blockade of the contribution of FXII in medical device associated thrombosis. Previous studies demonstrated that FXII activation is dependent on molecular cleavage after R353. We subsequently proposed that protein conformation protects this cleavage site to ensure zymogen quiescence and prevent inappropriate FXII activation. The AlphaFold model shows that a small loop containing R353 indeed is buried in the globular molecule. This is the result of intra-molecular interactions between the (N-terminal) Fibronectin type II domain, (central) kringle and (C-terminal) protease domain, in a structure that resembles a three-point harness. Furthermore, this interaction pushes the intermediate domains, as well as the flexible proline-rich region (PRR), outward while encapsulating R353 in the molecule. The outward directed positively charged patches are likely to be involved in binding to anionic surfaces. The binding of FXII to surfaces (and several monoclonal antibodies) acccelerates its activation by inducing conformational changes. For prevention of medical device associated thrombosis, it is therefore important to target the surface binding sites of FXII without causing structural changes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- CDL Research, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Förderung
- Trombosestichting Nederland
Zitieren
APA
Frunt, R., El Otmani, H., Gibril Kaira, B., de Maat, S., & Maas, C. (2023). Factor XII Explored with AlphaFold - Opportunities for Selective Drug Development. Thrombosis and Haemostasis, 123(02), 177-185. https://doi.org/10.1055/a-1951-1777
Vancouver
Frunt R, El Otmani H, Gibril Kaira B, de Maat S, Maas C. Factor XII Explored with AlphaFold - Opportunities for Selective Drug Development. Thrombosis and Haemostasis. 2023;123(02):177-185. doi:10.1055/a-1951-1777
BibTeX
@article{Frunt2023,
author = {Frunt, Rowan and El Otmani, Hinde and Gibril Kaira, Bubacarr and de Maat, Steven and Maas, Coen},
title = {Factor XII Explored with AlphaFold - Opportunities for Selective Drug Development},
journal = {Thrombosis and Haemostasis},
year = {2023},
volume = {123},
number = {02},
pages = {177--185},
doi = {10.1055/a-1951-1777}
}
EUVIMED